WO2006036213A3 - The use of gammaglobulin for the treatment of periodontal disease - Google Patents

The use of gammaglobulin for the treatment of periodontal disease Download PDF

Info

Publication number
WO2006036213A3
WO2006036213A3 PCT/US2005/014763 US2005014763W WO2006036213A3 WO 2006036213 A3 WO2006036213 A3 WO 2006036213A3 US 2005014763 W US2005014763 W US 2005014763W WO 2006036213 A3 WO2006036213 A3 WO 2006036213A3
Authority
WO
WIPO (PCT)
Prior art keywords
periodontal disease
treatment
gammaglobulin
immunoglobulin
oral administration
Prior art date
Application number
PCT/US2005/014763
Other languages
French (fr)
Other versions
WO2006036213A2 (en
Inventor
Leon E Barstow
Original Assignee
Pediamed Pharmaceuticals Inc
Leon E Barstow
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pediamed Pharmaceuticals Inc, Leon E Barstow filed Critical Pediamed Pharmaceuticals Inc
Publication of WO2006036213A2 publication Critical patent/WO2006036213A2/en
Publication of WO2006036213A3 publication Critical patent/WO2006036213A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to the method of prevention or treatment for onset and/or progression of immune-mediated periodontal disease using oral administration of immunoglobulin. More particular, periodontal disease and its defined conditions are treated using oral administration of immunoglobulin.
PCT/US2005/014763 2004-04-29 2005-04-28 The use of gammaglobulin for the treatment of periodontal disease WO2006036213A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56652304P 2004-04-29 2004-04-29
US60/566,523 2004-04-29

Publications (2)

Publication Number Publication Date
WO2006036213A2 WO2006036213A2 (en) 2006-04-06
WO2006036213A3 true WO2006036213A3 (en) 2006-05-26

Family

ID=35636955

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/014763 WO2006036213A2 (en) 2004-04-29 2005-04-28 The use of gammaglobulin for the treatment of periodontal disease

Country Status (1)

Country Link
WO (1) WO2006036213A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022530800A (en) * 2019-04-29 2022-07-01 ダイレクト バイオロジクス エルエルシー Treatment of periodontal disease using characterized mesenchymal stem cell growth factors and exosomes

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0148025A2 (en) * 1983-12-29 1985-07-10 Kitasato Kenkyusho Antibodies and antibody-containing compositions for inhibiting periodontitis
US4714612A (en) * 1984-06-28 1987-12-22 Lion Corporation Composition for oral application
US4911918A (en) * 1985-06-14 1990-03-27 Lion Corporation Oral composition containing stabilized antibody
DE4324859A1 (en) * 1992-07-23 1994-01-27 Lion Corp Oral compsn. for treating periodontal disease - contg. antibody obtd. by immunising animal with surface polysaccharide from pathogenic bacteria
WO1995013094A1 (en) * 1993-11-10 1995-05-18 Bristol-Myers Squibb Company Treatment of bacterially-induced inflammatory diseases
US5711937A (en) * 1993-06-28 1998-01-27 Lion Corporation Oral composition

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0148025A2 (en) * 1983-12-29 1985-07-10 Kitasato Kenkyusho Antibodies and antibody-containing compositions for inhibiting periodontitis
US4714612A (en) * 1984-06-28 1987-12-22 Lion Corporation Composition for oral application
US4911918A (en) * 1985-06-14 1990-03-27 Lion Corporation Oral composition containing stabilized antibody
DE4324859A1 (en) * 1992-07-23 1994-01-27 Lion Corp Oral compsn. for treating periodontal disease - contg. antibody obtd. by immunising animal with surface polysaccharide from pathogenic bacteria
US5711937A (en) * 1993-06-28 1998-01-27 Lion Corporation Oral composition
WO1995013094A1 (en) * 1993-11-10 1995-05-18 Bristol-Myers Squibb Company Treatment of bacterially-induced inflammatory diseases

Also Published As

Publication number Publication date
WO2006036213A2 (en) 2006-04-06

Similar Documents

Publication Publication Date Title
WO2005039504A3 (en) Compounds and methods for treating toll-like receptor 2-related diseases and conditions
WO2005046603A3 (en) Pyridine compounds
WO2004100881A3 (en) Preparation and use of aryl alkyl acid derivatives for the treatment of obesity
WO2006023649A3 (en) Treatment of severe multiple sclerosis
WO2005091853A3 (en) Methods and compositions for treating il-13 related pathologies
WO2006024018A3 (en) Compositions for treating nociceptive pain
WO2005028475A3 (en) Compositions useful as inhibitors of protein kinases
WO2006003388A3 (en) Compositions and methods for treating inflammatory disorders
WO2005061544A3 (en) Nogo-a neutralising immunoglobulins for treatment of neurological diseases
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
WO2003099110A3 (en) Herbs and herbal combinations useful for the treatment of microbial infections
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
WO2004113275A3 (en) Methods and compositions for treating amyloid-related diseases
WO2006003492A3 (en) Compositions and methods for treating pathological infections
WO2006034512A3 (en) Phenyl-substituted quinoline and quinazoline compounds for the treatment of diabetes
WO2003028668A3 (en) Gammaglobulin treatment of immune disorders
WO2006055871A3 (en) Treatment for multiple sclerosis
EP1638938A4 (en) Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
RS89204A (en) Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
WO2003099217A3 (en) Methods of treating bacterial infections and diseases associated therewith
WO2005002526A3 (en) Method and compositions for treatment of viral infections
WO2004091490A3 (en) Somatostatin-dopamine chimeric analogs
WO2004031105A3 (en) Use of a33 antigens and jam-it
WO2006135694A3 (en) Uii-modulating compounds and their use
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase